# JW Asset

> JW Asset is a VC fund backing Genetics, Health Care and Biotechnology. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 4
- Last investment: Dec 2021
- Lead investor: 25%
- Last updated: Aug 2026

JW Asset is a VC fund focused on Genetics and Health Care. South Korean Investment Firm

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Genetics | 1 | 25% |
| Health Care | 1 | 25% |
| Biotechnology | 1 | 25% |
| Bioinformatics | 1 | 25% |
| Pharmaceutical | 1 | 25% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 50% |
| Seed | 1 | 25% |
| Series C | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| DaNAgreen | DaNAgreen provides crosslink proteins to make scaffolds that help scientists culture cells in 3D. Their scaffolds can be easily manipulated in typical cell culture dishes, plates, and inserts in standardized procedures. | $6.8M | Series A | Dec 29, 2021 |  |
| 3billion | 3billion was founded with the goal of ending the diagnostic odyssey of rare disease patients through comprehensive genetic testing. It has reduced the amount of time and cost that was previously required for genome interpretation by using bioinformatics and machine learning technology, making genome-scale rare disease genetic testing affordable forpatients in need.The company was established in 2016 and is headquartered in Seoul, South Korea. | $13M | Series C | Mar 26, 2021 |  |
| DaNAgreen | DaNAgreen provides crosslink proteins to make scaffolds that help scientists culture cells in 3D. Their scaffolds can be easily manipulated in typical cell culture dishes, plates, and inserts in standardized procedures. | $1.3M | Seed | Aug 20, 2020 |  |
| 3billion | 3billion was founded with the goal of ending the diagnostic odyssey of rare disease patients through comprehensive genetic testing. It has reduced the amount of time and cost that was previously required for genome interpretation by using bioinformatics and machine learning technology, making genome-scale rare disease genetic testing affordable forpatients in need.The company was established in 2016 and is headquartered in Seoul, South Korea. | $2.2M | Series A | Jul 11, 2018 |  |

4 of 4 investments shown.

## Co-investors
- [The Wells Investment](https://shizune.co/investors/profile/the-wells-investment) — VC Fund, 2 deals together
- [AVentures Capital](https://shizune.co/investors/profile/aventures-capital) — VC Fund, 1 deal together
- [D3 Jubilee](https://shizune.co/investors/profile/d3jubilee) — VC Fund, 1 deal together
- [Digital Healthcare Partners](https://shizune.co/investors/profile/digital-healthcare-partners) — VC Fund, 1 deal together
- [Hi Investment Partners](https://shizune.co/investors/profile/hi-investment-partners) — VC Fund, 1 deal together
- [Hi Investment Partners](https://shizune.co/investors/profile/hi-investment-partners-b81a) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Strong Ventures](https://shizune.co/investors/profile/strong-ventures) — VC Fund
- [Korea Credit Guarantee Fund](https://shizune.co/investors/profile/korea-credit-guarantee-fund) — VC Fund
- [Kakao Ventures](https://shizune.co/investors/profile/kakao-ventures) — VC Fund

## Featured in investor lists
- [Biotech Investors in South Korea](https://shizune.co/investors/biotech-investors-south-korea)
- [Biotech VC Funds in South Korea](https://shizune.co/investors/biotech-vc-funds-south-korea)
- [Biotechnology Investors in South Korea](https://shizune.co/investors/biotechnology-investors-south-korea)
- [Biotechnology VC Funds in South Korea](https://shizune.co/investors/biotechnology-vc-funds-south-korea)
- [Health Care Investors in South Korea](https://shizune.co/investors/health-care-investors-south-korea)
- [Health Care VC Funds in South Korea](https://shizune.co/investors/health-care-vc-funds-south-korea)

## FAQ

### What does JW Asset invest in?

JW Asset invests primarily in Genetics, Health Care and Biotechnology startups, most often at Series A and Seed stage. Most of the 4 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did JW Asset last invest?

The most recent investment recorded for JW Asset closed in Dec 2021. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co